The validity and sensitivity of <scp>PANSS</scp>‐6 in treatment‐resistant schizophrenia

Østergaard, Søren Dinesen; Foldager, Leslie; Mors, Ole; Bech, Per; Correll, Christoph U.

doi:10.1111/acps.12952

Cited by 22 publications

(14 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Relatedly, we also found a strong correlation between the PANSS-6 total scores obtained using the SNAPSI and the PANSS-8 total scores, suggesting that the PANSS-6 explains a very large fraction of the variance in the PANSS-8, which represents the items of the remission criteria (Andreasen et al, 2005) and the core diagnostic criteria of schizophrenia, thereby confirming the content and construct validity of the PANSS-6 via the SNAPSI approach (American Psychiatric Association, 1994;WHO, 1993). The correlation between the PANSS-6 total scores obtained using the SNAPSI and the PANSS-30 total score obtained using the SCI-PANSS was lower compared to our previous studies (Lin et al, 2018;Østergaard et al, 2016, 2018a, 2018b. This result is likely due to the fact that the PANSS-6 was extracted from the PANSS-30 ratings in the previous studies and thereby not affected by inter-rater reliability and test-retest reliability as in the present study where the ratings were conducted by independent raters on the basis of independent interviews.…”

Section: Discussioncontrasting

confidence: 88%

See 1 more Smart Citation

Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview

et al. 2021

View full text Add to dashboard Cite

Background: The six-item version of the Positive and Negative Syndrome Scale (PANSS-6) has shown promise as a brief measure of the severity of core symptoms of schizophrenia. However, since all prior analyses of the PANSS-6 were based on data extracted from studies using the full 30-item PANSS (PANSS-30), it remains unknown whether it is possible to obtain valid information for the PANSS-6 ratings via a brief interview, such as the Simplified Negative and Positive Symptoms Interview (SNAPSI). Aims: We aimed to validate the PANSS-6 ratings obtained via the SNAPSI using the PANSS-6 scores extracted from the PANSS-30 ratings obtained via the comprehensive Structured Clinical Interview for PANSS (SCI-PANSS) as the gold-standard reference. Methods: The PANSS-6 ratings based on the SNAPSI and the PANSS-30 ratings based on the SCI-PANSS were conducted by independent raters with established inter-rater reliability. Results: Seventy-seven inpatients with schizophrenia ( Mage = 35.1 ± 11.7 years; males = 57%; paranoid schizophrenia = 75%) participated in the study. The intraclass correlation coefficient (ICC) of the PANSS-6 total scores obtained using the SNAPSI and the PANSS-30-derived PANSS-6 total scores via the SCI-PANSS was 0.77 ( p < 0.001). The ICC for the PANSS-6 total score and the PANSS-30-derived PANSS-8 (Andreasen’s remission criteria) was 0.75 ( p < 0.001). Spearman’s rank correlation coefficient for changes in PANSS-6 total scores via the SNAPSI and changes in PANSS-30-derived PANSS-6 total scores was 0.70 ( p < 0.001). Conclusions: Using the SNAPSI to rate the PANSS-6 enables a focused and brief assessment of the severity of core symptoms of schizophrenia, which facilitates measurement-based care and clinical decision making in the treatment of schizophrenia.

show abstract

Section: Discussioncontrasting

confidence: 88%

“…The good psychometric properties of the PANSS-6 have already been established (Lin et al, 2018;Østergaard et al, 2016, 2018a, 2018b. However, the primary limitation of these studies was that the PANSS-6 ratings were extracted from the PANSS-30 ratings via the SCI-PANSS.…”

Section: Discussionmentioning

confidence: 99%

Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview

et al. 2021

View full text Add to dashboard Cite

show abstract

“…PANSS is a 30 item scale used to quantify the severity of positive symptoms, negative symptoms, and general psychopathy in subjects with schizophrenia. 49 – 51 The primary endpoint changed from baseline in the sum of all participants’ PANSS score to Week 6.…”

Section: Discussionmentioning

confidence: 99%

<p>Transdermal Asenapine in Schizophrenia: A Systematic Review</p>

Carrithers¹,

El‐Mallakh²

2020

PPA

View full text Add to dashboard Cite

Background: Asenapine is a novel antipsychotic that has demonstrated efficacy in controlling psychosis in schizophrenia and mania in bipolar illness. It must be administered as a sublingual formulation because it is nearly completely metabolized in the first pass through the liver. Recently, a transdermal formulation of asenapine has been approved for schizophrenia by the Food and Drug Administration. Methods: A systematic review of transdermal asenapine was done utilizing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) model. Discussion: There are several formulations of transdermal asenapine but only Secuado ® has been approved for clinical use. Total bioavailability is 35%. Peak plasma concentration (Cmax) is 4 ng/mL and occurs within 1 hr (Tmax); elimination half-life (t 1/2) is 24 hrs (range 13.4 to 39.2 h). Asenapine is highly bound (95%) to albumin and α 1-acid glycoprotein. It has a unique receptor profile in which it functions as an antagonist at multiple receptors with affinity that is higher than D 2 (K i = 1.3) including D 3 , D 4 , 5HT 2A , 5HT 2C , 5HT 2B , 5HT 7 , 5HT 6 , H 1 , and α2. This profile suggests that asenapine may be of particular value off label for bipolar depression, anxiety, and aggression. Transdermal asenapine was only tested in one randomized, placebo-controlled study of acute psychosis in schizophrenia. It was superior to placebo at week 6 with nearly onethird of patients experiencing >30% improvement in total PANSS score which translates in a number needed to treat (NNT) of 9.

show abstract

“…The PANSS-6 subscale includes three items measuring positive symptoms (P1 Delusions, P2 Conceptual disorganization, and P3 Hallucinatory behavior) and three items measuring negative symptoms (N1 Blunted affect, N4 Passive/apathetic social withdrawal, and N6 Lack of spontaneity and flow of conversation). The sensitivity of the PANSS-6, when extracted from PANSS-30 assessments, has previously been found to match that of the PANSS-30 as far as antipsychotic–placebo differences 7 and differences between antipsychotics are concerned 8 , 9 . The PANSS-6 also has a high rate of agreement with the PANSS-based definition of symptom remission from the Remission in Schizophrenia Working Group 2 , 8 , 9 .…”

Section: Introductionmentioning

confidence: 91%

Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis

et al. 2021

View full text Add to dashboard Cite

In order for measurement-based care to be implemented, there is a need for brief rating instruments that can be administered in a short amount of time, but that are still sufficiently informative. Here, we assessed the drug–placebo sensitivity of the six-item subscale (PANSS-6) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) using a large collection of patient-level data (n = 6685) from randomized controlled trials of risperidone and paliperidone. When analyzing the data by study, we found no material difference in mean effect sizes (ES) between the two measures (PANSS-30 ES = 0.45, PANSS-6 ES = 0.44; p = 0.642). Stratifying the pooled population according to several putative effect moderators (e.g., age, formulation, dose, or diagnosis) generally yielded no meaningful ES differences between the two measures. Similarly, early improvement (≥20% improvement at week 1) on the PANSS-6 predicted subsequent response (≥40% improvement at endpoint) as well as the analog prediction using PANSS-30. Finally, cross-sectional symptom remission assessed via the PANSS-6 showed very good agreement (sensitivity = 100%, specificity = 98%) with cross-sectional symptom remission defined by the Remission in Schizophrenia Working Group.

show abstract

The validity and sensitivity of PANSS‐6 in treatment‐resistant schizophrenia

Abstract: PANSS-6 validly measures severity, remission and antipsychotic efficacy in TRS.

Cited by 22 publications

References 42 publications

Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview

Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview

<p>Transdermal Asenapine in Schizophrenia: A Systematic Review</p>

Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis

Contact Info

Product

Resources

About